(Q55239244)

28 June 2018

title

Cost-effectiveness of additional blood screening tests in the Netherlands. (English)

1 reference

28 June 2018

main subject

Netherlands

0 references

author name string

Barbara A Borkent-Raven

1

1 reference

28 June 2018

Mart P Janssen

2

1 reference

28 June 2018

Cees L van der Poel

3

1 reference

28 June 2018

Gouke J Bonsel

4

1 reference

28 June 2018

Ben A van Hout

5

1 reference

28 June 2018

publication date

31 August 2011

1 reference

28 June 2018

published in

Transfusion

1 reference

28 June 2018

volume

52

1 reference

28 June 2018

issue

3

1 reference

28 June 2018

page(s)

478-488

1 reference

28 June 2018

The hazards of blood transfusion in historical perspective

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03319.X

Pharmaco-economics of blood transfusion safety: review of the available evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03319.X

The NICE cost-effectiveness threshold: what it is and what that means

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03319.X

Costs and benefits of bacterial culturing and pathogen reduction in the Netherlands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03319.X

Cost-effectiveness of leucocyte-depleted erythrocyte transfusion in cardiac valve surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03319.X

The PROTON study: profiles of blood product transfusion recipients in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03319.X

Human T-cell lymphotropic virus testing of blood donors in Norway: a cost-effect model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03319.X

Persistence of HTLV-I in blood components after leukocyte depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03319.X

The prevalence of antibodies to hepatitis A virus and its determinants in The Netherlands: a population-based survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03319.X

Cost-effectiveness of additional hepatitis B virus nucleic acid testing of individual donations or minipools of six donations in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03319.X

A model of the health and economic impact of posttransfusion hepatitis C: application to cost-effectiveness analysis of further expansion of HCV screening protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03319.X

Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03319.X

Regional variation in the cost effectiveness of childhood hepatitis A immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03319.X

Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window-phase donations not detected by NAT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03319.X

Emerging infectious disease agents and their potential threat to transfusion safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03319.X

Screening for human T cell leukaemia/lymphoma virus among blood donors in Sweden: cost effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03319.X

Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03319.X

Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03319.X

Cost-effectiveness of expanded human immunodeficiency virus-testing protocols for donated blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03319.X

Value and cost-effectiveness of screening blood donors for antibody to hepatitis B core antigen as a way of detecting window-phase human immunodeficiency virus type 1 infections. The HIV Blood Donor Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03319.X

Including polymerase chain reaction in screening for hepatitis C virus RNA in blood donations is not cost-effective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03319.X

The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2011.03319.X

10.1111/J.1537-2995.2011.03319.X

21 January 2018

Identifiers

DOI

1 reference

28 June 2018

1 reference

28 June 2018